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We describe the epidemiology, clinical features, and 
molecular characterization of enterohemorrhagic Esche-
richia coli (EHEC) infections caused by the singular hybrid 
pathotype	 O80:H2,	 and	 we	 examine	 the	 influence	 of	 
antibiotics on Shiga toxin production. In France, dur-
ing 2005–2014, a total of 54 patients were infected with 
EHEC	O80:H2;	91%	had	hemolytic	uremic	syndrome.	Two	 
patients had invasive infections, and 2 died. All strains 
carried stx2 (variants stx2a, 2c, or 2d); the rare intimin 
gene (eae-ξ);	and	at	least	4	genes	characteristic	of	pS88,	
a plasmid associated with extraintestinal virulence. Simi-
lar strains were found in Spain. All isolates belonged to 
the same clonal group. At subinhibitory concentrations, 
azithromycin	decreased	Shiga	toxin	production	significant-
ly,	ciprofloxacin	increased	it	substantially,	and	ceftriaxone	
had no major effect. Antibiotic combinations that included 
azithromycin	also	were	tested.	EHEC	O80:H2,	which	can	
induce hemolytic uremic syndrome complicated by bac-
teremia, is emerging in France. However, azithromycin 
might effectively combat these infections.
Enterohemorrhagic Escherichia coli (EHEC) are a sub-set of Shiga toxin–producing E. coli (STEC) that cause 
diarrhea and hemorrhagic colitis; illness can progress to 
hemolytic uremic syndrome (HUS) in 5%–10% of cases 
(1,2). HUS is the most frequent etiology of pediatric acute 
renal failure, and its lethality is 3%–5% worldwide (1,3) 
and 1% in France (4). Long-term renal injuries occur in 
20%–30% of HUS patients (1,3,5).
EHEC serotype O157:H7 accounts for ≈60% of HUS 
cases worldwide (6,7). Other well-known serogroups as-
sociated with HUS include O26, O111, O145, O55, O103, 
O121, and O91. EHEC O80:H2 strains are rarely reported in 
the literature but have been detected in France. In 2013, an 
EHEC O80:H2 strain was responsible for a severe case of 
HUS with relapse associated with bacteremia (8). We identi-
fied several genetic traits in this isolate, such as a rare variant 
of the intimin gene (eae-ξ) and genetic determinants related 
to the pS88 plasmid associated with extraintestinal-virulence 
pathogenic E. coli (ExPEC) (9). This plasmid, mainly found 
in avian pathogenic E. coli and E. coli strains that cause 
neonatal meningitis, may partly explain the bacteremia ob-
served, which has been reported in patients with HUS.
The occurrence of bacteremia during EHEC infections 
warrants antibiotic treatment for those infections. How-
ever, antibiotics usually are not recommended for EHEC 
infection because of the risk for worsening HUS, notably 
by induction of synthesis or secretion of Shiga toxin (Stx) 
(1,10–12). Therefore, bacteremia during EHEC infection 
represents a new therapeutic challenge. However, a 2011 
outbreak in Germany linked to EHEC O104:H4 (13) un-
derscored the potential benefit of certain antibiotics when 
HUS occurs (14,15). Thus, the use of antibiotics during 
EHEC infections remains a source of debate (2,16).
Our study aimed to determine the incidence rate of 
HUS cases associated with the singular EHEC O80:H2, 
describe their clinical features, and examine the molecular 
characteristics of the strains. In addition, we assessed the 




For this study, we considered all E. coli O80:H2 isolates 
received during January 2005–October 2014 by the Cen-
tre National de Référence Associé Escherichia coli (Paris, 
France). We then collected demographic and clinical data 
from patients’ medical records (e.g., age, sex, location); 
presence of diarrhea (with or without blood); possible 
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source of infection; presence of neurologic or other compli-
cations (including pancreatitis, hepatitis, myocarditis, and 
bacteremia); whether the patient had HUS; and outcome at 
time of follow-up (e.g., relapse, residual renal injuries [in-
cluding proteinuria and renal failure], arterial hypertension, 
or death). HUS was defined as anemia (hemoglobin <10 
g/dL), thrombopenia (platelets <150,000/mm3), and renal 
failure (creatinine above reference for age, weight, and sex, 
or >0.2 protein/creatinine ratio). 
Bacteria Strains
We recovered isolates 35344 and 35431 from stool and 
blood cultures, respectively, of a HUS patient who was the 
subject of a recent case report (8). These strains belonged 
to sequence type 301 and harbored 4 intestinal virulence 
genes (stx2c, stx2d, hlyA, and eae-ξ) and most of the ex-
traintestinal virulence genes carried by plasmid pS88 (8). 
The Laboratoire National de Réference pour les Escherich-
ia coli (Marcy l’Etoile, France) and reference laboratories 
from Spain, Italy, and Germany were associated with this 
study and provided us with their EHEC O80 strains when 
available. The reference strain EDL933 (O157:H7, stx1a, 
stx2a, and eae-γ) served as the control in the study of Stx 
production (17). We stored all EHEC strains at –80°C in 
5% glycerol.
Serotyping
The Centre National de Référence des Escherichia coli, 
Shigella, et Salmonella at the Institute Pasteur (Paris, 
France) initially determined the O80 serogroup by using a 
method based on the analysis of the O antigen genes clus-
ter rfb restriction fragments length polymorphism (18); this 
result was recently confirmed by O80-specific PCR with 
primers targeting O80 polymerase gene wzy (GenBank ac-
cession no. AB812032). This new PCR was included in our 
previously described O-serogroup multiplex PCR (19). We 
assessed specificity of the new multiplex PCR on template 
DNA extracted from 130 O reference strains as previously 
described (20). Primers used for the EHEC O-serogrouping 
multiplex PCR are provided (online Technical Appendix 
Tables 1, 2, http://wwwnc.cdc.gov/EID/article/22/9/16-
0304-Techapp1.xlsx). We determined the H serogroup by 
using PCR targeting the fliC genes (21).
Molecular Characterization
Among EHEC O80 strains, we screened several genetic de-
terminants by multiplex PCR as previously described (22), 
including intestinal virulence genes (stx1, stx2, eae, and 
hlyA) and extraintestinal virulence genes associated with 
plasmid pS88 (sitA, eitB, cia, iss, iucC, iroN, hlyF, etsC, 
cvaA, and ompTp) (9,23). We also determined the variants 
of stx2 (stx2a, stx2b, stx2c, and stx2d) and the variant of 
eae by using PCR-based methods (24,25).
To investigate the genetic diversity of the O80:H2 
strains studied, we used the DiversiLab genotyping method 
(bioMérieux, Marcy-l’Étoile, France), which is based on 
PCR amplification of repeat sequences of DNA (rep-PCR) 
as previously described (26). We then compared these 
genotypes with representative strains of serogroups (O157, 
O104, O121, and O111) previously typed and recorded in 
our DiversiLab database (S. Bonacorsi, unpub. data).
Effect of Various Antibiotics on Stx Production
We prepared inocula to assess Stx production in the pres-
ence or absence of antibiotics as previously described (27). 
We obtained log-phase growth of strains in brain–heart in-
fusion broth by using overnight incubation at 37°C and then 
diluted the result with Luria-Bertani broth for an inoculum 
of 106 CFU/mL. We added 3 antimicrobial agents (azithro-
mycin, ciprofloxacin, and ceftriaxone) at final MICs of 0.5 
and 0.25 for a single assay. We also tested combinations 
of antibiotics at a MIC of 0.5. For each strain, we also per-
formed an antibiotic-free assay. We collected the bacterial 
cultures after 18 h of incubation at 37°C and centrifuged 
at 4°C at 2,000 rpm for 10 min. We filtered supernatants 
through a 0.22-µm pore-size filter (Millipore, Bedford, 
MA, USA) and stored at –20°C until needed.
We quantified Stx1 and Stx2 by using a chemilumi-
nescent immunoassay for EHEC toxins (Liaison, DiaSorin, 
Spain). We expressed the results in relative light units, and 
converted each result to a concentration of Stx (ng/mL) by 
using a standard curve obtained by serial dilution of a high-
ly positive sample and the manufacturer-provided positive 
control (70 ng/mL Stx concentration). We performed each 
measure 3 times.
Statistical Analysis
We calculated means, medians, and SDs in Excel (Microsoft 
Corp., Redmond, WA, USA). Student paired t-test was used 
to compare means of Stx concentrations; p values <0.05 
were considered statistically significant. Quantitative vari-
ables are presented as median and range or quartile range.
Results
During January 2005–October 2014, the Centre National 
de Référence Associé Escherichia coli collected 57 strains 
of EHEC O80:H2 in France. These strains were isolated, 
mostly from stool specimens, from 54 patients; 2 and 3 
isolates each were recovered from 2 patients. Clinical data 
were available for all but 1 patient.
The spatiotemporal distribution of the O80:H2 infec-
tions clearly indicates an increased number of infections 
during the past 5 years (Figure 1). In 2014, the EHEC O80 
serogroup was the second-leading cause of pediatric HUS 
in France (4). Most of the cases occurred during summer 
and the beginning of autumn. Geographic distribution of 
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O80:H2 EHEC infections in France revealed high 10-year 
cumulative incidences (>1/100,000) in Franche-Comté 
(2.83/100,000 children) and in Rhône-Alpes (1.19/100,000 
children), contrasting with the distribution of O157 infec-
tions, which are rarely detected in these areas (Figure 2).
Among the 53 patients for whom clinical data were 
available, 48 (91%) had HUS; 27 (51%) were male. Me-
dian age for these 48 patients was 1.2 years (range 0.2–
39 years, interquartile range [IQR] 0.7–1.6 years). Only 
1 adult HUS patient (a 39-year-old) was reported. The 5 
(9%) non-HUS patients were largely older (1, 2, 6, 21, and 
40 years old). Among HUS patients, fever was present in 
45%; median leukocyte count was 13,000 cells/mm3 (data 
were not available for 14 patients), and 56% had leuko-
cytosis (>11,500 leukocytes/mm3) (online Technical Ap-
pendix Table 3). Diarrheal illness was reported for 83% 
of HUS patients (bloody diarrhea for 30%); median time 
from onset of diarrhea to diagnosis of HUS was 6 days 
(data available for 37 patients). Diarrheal illness in family 
members was recorded in only 2 HUS cases. One patient 
had a relapse complicated by bacteremia (8), 1 patient died 
after myocardial complication with pancreatic abscess 
from which an O80:H2 EHEC strain was isolated, and 1 
patient died from septic shock with intestinal necrosis and 
peritonitis. Eight (17%) cases of neurologic complication 
(17%) were reported. All the neurologic complications 
were seizures (documented in 6 cases by imaging) with 
ischemic strokes. Among the 8 patients with neurologic 
complications, 2 died, and 1 has difficulty concentrating 
(19 months after HUS); for 1 patient, the neurologic state 
could not be assessed, and for 4 others, the neurologic out-
come was favorable.
Of the 48 HUS patients, 27% needed acute dialysis 
support (median duration 10 days, range 3–21 days, IQR 
7.4–13.5 days), and 28% had long-term renal sequelae, 
including proteinuria for all cases, hypertension in 3 cas-
es, and chronic renal failure in 1 case (median follow-
up duration 8 months, range 1–108 months, IQR 2–41 
months). Finally, only 21% of medical records mentioned 
the possible source of infection, and no hypothesis could 
be formulated. 
Genetic characterization showed that all O80:H2 
strains of human origin collected in France carried the stx2 
genes and no stx1 genes (online Technical Appendix Ta-
ble 3). The stx2 subtype could not be determined for the 2 
strains (isolated in 2006 and in 2010) because they had lost 
their stx2 gene despite preservation at –80°C. Among the 
remaining strains, 69% had a combination of stx2 variants, 
stx2c/2d (62%) and stx2a/2d (7%); 31% harbored unique 
variants, stx2a (22%) and stx2d (9%). All strains had the in-
timin encoding gene eae and its variant eae-ξ, and 87% car-
ried the enterohemolysin ehxA gene. All 57 strains shared 
>4 characteristic genes of the pS88 plasmid, sitA, cia, hlyF, 
and ompTp; 98% had the iss and iroN genes; 96% had the 
cvaA gene; and 61% had the iucC and etsC genes (online 
Technical Appendix Table 3).
Antimicrobial drug susceptibility testing revealed that 
most strains were multidrug resistant; rates of resistance 
were 91% for amoxicillin, 89% for nalidixic acid, 82% for 
cotrimoxazole, and 71% for kanamycin (online Technical 
Appendix Table 3). Overall, 52% of the strains were resis-
tant to all 4 antibiotics.
To examine whether an animal could be the potential 
source of EHEC O80:H2, we solicited the Laboratoire Na-
tional de Réference pour les Escherichia coli. Only 1 strain 
from an animal source (LNR-511-4, isolated from raw cow 
milk cheese) was available. This strain carried eae-ξ, ehxA, 
and stx2a genes and 7 genes associated with the pS88 plas-
mid related to ExPEC (sitA, cia, iss, iroN, hlyF, cvaA, and 
ompTp). This strain also was resistant to amoxicillin, kana-
mycin, and nalidixic acid.
To investigate the distribution in Europe of this emerg-
ing EHEC serogroup, several national reference laboratories 
in Europe were associated with this study and were asked 
to send us their available EHEC O80 strains. We obtained 5 
strains from Spain, whereas Italy and Germany had no such 
strain in their collections. Among the 5 strains from Spain, 
3 were of human origin (IH42632/03a, IH33264/ 07a, and 
IH102878/12a) and 2 were of animal origin (VTB-262 
from a cow and FV4476 from a pig [the pig-origin strain 
was actually isolated in Slovakia]) (28). All 5 strains shared 
eae-ξ, but stx2 (stx2a) was found in only 2 strains (both 
of human origin), and none had ehxA. Only the 3 human 
strains harbored most of the investigated genes associated 
with pS88. The contrast between animal strains and human 
strains from the national reference laboratory in Spain was 
also evident in their antibiotic-resistance profiles; only the 
human strains were multidrug resistant (online Technical 
Appendix Table 3).
To analyze the genetic diversity and genetic related-
ness with other EHEC serogroups, all the O80:H2 strains 
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Figure 1.	Number	of	enterohemorrhagic	Escherichia coli	O80:H2	
strains detected annually, France, January 2005–October 2014.
Enterohemorrhagic E. coli	O80:H2
were analyzed by using rep-PCR and compared with some 
other serogroups (O157, O104, O111, and O121) (Figure 
3). All EHEC O80:H2 strains shared 95% similarity except 
strain IH102878/12a from Spain (90% similarity). These 
data suggest that almost all EHEC O80 strains belong to a 
unique clonal group, regardless of their geographic origin 
and source (human or animal). EHEC O80:H2 strains were 
genetically distant to representative strains of serogroups 
O157, O104, O111, and O121.
To study the effect of antibiotics on Stx production in 
O80:H2 EHEC strains, we selected 4 representative strains 
(33115, 35344, 35431, and 36047) based on their genotyp-
ic and clinical characteristics (online Technical Appendix 
Table 3). Strain EDL933 (O157:H7) served concomitantly 
as the control. We examined susceptibility to the 3 antibiot-
ics (Table). First, we estimated the basal production of Stx 
in different strains after 18 h of growth without antibiot-
ics (Figure 4). The basal production among the different 
O80:H2 strains were comparable but significantly lower 
compared with that of strain EDL933, which produces 
≈100-fold more Stx than certain O80:H2 strains (35344 
and 36047). We could not separately estimate the respec-
tive rates of Stx1 and Stx2.
For each strain, we examined the influence of the 3 
antibiotics at concentrations below the MICs expressed 
as relative secretion of Stx compared with basal secretion 
(without antibiotics) after 18 hours’ incubation period (Fig-
ure 5, panels A–E). Overall, azithromycin was responsible 
for >5-fold decreases of Stx production in all O80:H2 
strains at a MIC of 0.5. As expected, the same effect was 
observed with the EDL933 strain. At all concentrations 
tested, ciprofloxacin significantly induced a major increase 
of Stx secretion for all strains except strain 35344. The in-
crease was particularly marked for O80:H2 strains com-
pared with O157 strains; a 100-fold increase was observed 
for 33115 and 35431 (Figure 5, panels B and C), compared 
with a 6-fold increase for EDL933 (Figure 5, panel E). 
Ceftriaxone, in contrast with other antibiotics, did not sig-
nificantly alter Stx production except for 1 O80:H2 strain 
(Figure 5, panel C).
Finally, we wanted to determine whether the beneficial 
effect of azithromycin on Stx production would persist in 
the presence of 2 other antibiotics, a combination which 
might be used in cases of bacteremia. The combinations 
of antibiotics were tested on 2 O80:H2 strains (Figure 6). 
Azithromycin paired with ciprofloxacin significantly re-
duces Stx production compared with ciprofloxacin alone. 
However, this production was higher than that observed 
with azithromycin alone, and for both strains, Stx levels 
were higher for azithromycin/ciprofloxacin compared with 
no antibiotic. These data indicate that the macrolide might 
only partially inhibit the noxious effect of ciprofloxacin. 
The effect of azithromycin in combination with ceftriax-
one depended on the strain tested. For strain 35344, the as-
sociation slightly increased Stx production compared with 
ceftriaxone, whereas for strain 33115, the opposite was 
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Figure 3. Dendrogram 
obtained after DiversiLab 





humans in France compared 
with other isolates detected 
in France, Germany, and 
Spain, January 2005–October 
2014. Other isolates include 1 
animal-origin strain from France 
(LNR511-4,	bovine,	2012);	
5 animal- and human-origin 
isolates from Spain (FV4476, 
porcine; VTB-262, bovine; 
IH43632/03a,	IH33264/07a,	
and	IH	102878/12a,	human);	
and 6 comparison strains from 
other	serogroups	(EDL933	and	
32031, O157; 32527 and 32573, 
O104, isolated during a 2011 




observed. However, in this experiment, the observed Stx 
rate was lower in ceftriaxone and azithromycin/ceftriaxone 
assays compared with basal secretion.
Discussion
In this study, we described the emergence in France of a 
new virulent EHEC serotype, O80:H2, that harbors sin-
gular genetic characteristics of a hybrid STEC/ExPEC 
pathotype. Several important conclusions can be drawn.
First, the EHEC O80:H2 strain appears to be at least as 
virulent as the EHEC O157:H7 strains present in France. 
Indeed, the rate of HUS-associated complications, such as 
renal injuries (28%) and death (4%), of the O80:H2 strain 
were comparable with that of O157:H7 (1,4). Moreover, 
EHEC O80:H2 isolates have the particular properties to in-
duce invasive infections; >2 of the 53 patients affected had 
bacteremia or deep abscess. Extraintestinal infections very 
rarely are associated with EHEC; to our knowledge, only 6 
cases of bacteremia have been previously described in the 
context of HUS (8). None of these 6 reports extensively 
searched for extraintestinal virulence factors. Whether the 
extraintestinal virulence of EHEC O80:H2 is related to the 
presence of genetic traits characteristic of an extraintestinal 
virulence–associated plasmid remains to be determined. 
Identification of the salmochelin-encoding genes (iroN) in 
98% of the EHEC O80:H2 from France is of particular in-
terest. This gene is clearly involved in the pathophysiology 
of E. coli bacteremia and meningitis (9,29).
Because the surveillance system for STEC is voluntary 
in France and because stx-specific PCR is performed only 
in cases involving diarrhea with HUS suspicion, accurate 
data are not available on the rates of diarrhea without HUS 
or of bloodstream infections caused by this serotype and 
others. Only cases of diarrhea occurring among HUS pa-
tient contacts are systematically investigated. Therefore, 
many cases of O80:H2-related diarrhea are probably un-
diagnosed, and we cannot draw any conclusion concerning 
the risk for HUS in cases of diarrhea associated with STEC 
O80:H2. Moreover, non-HUS cases of bacteremia caused 
by O80:H2 strains will escape detection.
We were not able to identify the potential source of this 
emerging EHEC pathotype. All reported cases have been 
sporadic, and the possibility of foodborne infection remains 
speculative, even though O80:H2 strains were isolated from 
few animals. The highest incidence of O80:H2 infection was 
observed in regions of France where EHEC O157 infections 
are not predominant, suggesting a possible atypical route 
or source of infection. Although Spain does not share bor-
ders with the high-incidence regions of France, it was the 
only country where a significant number of EHEC O80:H2 
strains were found. Two O80:H2 EHEC strains from Spain 
(IH102878/12a and IH33264/07a) were very similar to 
French strains belonging to the same clonal group with a sim-
ilar virulence genotype, suggesting a direct lineage between 
the isolates in Spain and France. As is usually observed for 
other serotypes, most of the infections with these strains oc-
curred during summer and the beginning of autumn (4,7).
The molecular characterization of the EHEC O80:H2 
strains was of particular interest. The presence in all 
strains from Spain and France of the very rare eae-ξ gene 
combined with results of the genetic diversity study us-
ing rep-PCR strongly indicate that these strains, what-
ever their origin, have a common ancestor combining the 
O80:H2 serotype and an eae-ξ gene containing LEE. On 
this unique genetic background, several genetic events oc-
curred: the acquisition of >1 prophage encoding Stx, the 
presence of a plasmid similar to that found in ExPEC, and 
the presence of a plasmid encoding enterohemolysin. The 
chronology of these events remains speculative. However, 
acquisition of Stx2-encoding genes seems to remain par-
ticularly active because 3 different variants in >4 differ-
ent modes (in combination or alone) were observed. The 





Table. Antibiotic susceptibility of enterohemorrhagic Escherichia coli O80:H2	and	O157:H7	isolates used in an antibiotics assay, 
France, January 2005–October 2014 
Isolate (source) Serotype 
MIC,	µg/mL 
Azithromycin Ciprofloxacin Ceftriaxone 
35344 (stool) O80:H2 1 0.5 0.25 
35431 (blood) O80:H2 16 0.5 0.06 
33115 (pancreas) O80:H2 16 0.25 0.06 
36047 (stool) O80:H2 16 0.06 0.06 
EDL933	(ground	beef) O157:H7 32 0.12 0.12 
 
Figure 4. Mean concentrations (logarithmic scale) of Shiga 
toxin produced in the absence of antibiotics by selected strains 
of enterohemorrhagic Escherichia coli	serotypes	O80,	France,	
January	2005–October	2014.	O157	reference	strain	(EDL933)	
was used as control. Error bars indicate SDs.
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combination suggests the interplay of certain plasmidic 
determinants and intestinal pathogenic traits. The mini-
mal combination of plasmidic genes common to all strains 
was the association of ompTp and hlyF, which might rep-
resent a beneficial influence on the intestinal pathogenic 
virulence of E. coli O80:H2. Chromosomal ompT and 
hlyF are involved in the secretion of outer membrane 
vesicles, which might serve as transporters of toxins and 
thus might boost the virulence of Stx-producing E. coli 
(30,31). Whether ompTp has a similar role remains to be 
further investigated.
Finally, clinical features and molecular character-
ization indicating the potential invasive pathogenicity of 
EHEC O80:H2 raise the question of which antibiotic should 
be used in such infections. Several clinical studies have 
suggested a deleterious effect of antibiotics during EHEC 
infection, leading to recommendations to not use such 
treatment (2). The major explanation of such an adverse 
effect is the induction of Stx secretion through the SOS 
response, which is stimulated by antibiotics such as fluo-
roquinolones in vitro and in experimental models (32,33). 
Several studies demonstrated that the effect of antibiotics 
on HUS depends on their class (27,33–37). Ciprofloxacin 
raises the production and release of Stx in vitro and is asso-
ciated with a higher mortality rate in pigs (33). Other stud-
ies have shown that some antibiotics such as azithromycin 
might be associated with a decrease of the production and 
release of Stx in vitro (37) and with favorable outcomes in 
in vivo studies in piglets and mice (33,38). Finally, during 
a 2011 outbreak of EHEC O104 infection in Germany, a 
patient treated by ciprofloxacin plus imipenem unexpect-
edly had a better prognosis than all others (14). This result 
suggests that response to antibiotics might also differ de-
pending of the strain involved (34). 
Our analysis of Stx production in the presence of an-
tibiotics has clearly indicated that ciprofloxacin should 
not be used in cases of EHEC O80 infection. In contrast, 
azithromycin provided a beneficial in vitro effect and might 
be useful in cases of EHEC O80–associated diarrhea. These 
results are consistent with the systematic review by Agger 
et al. (16), who concluded that a protein synthesis inhibitor 
can be considered during EHEC infections when specific 
criteria are met. To our knowledge, only a few studies have 
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Figure 5. Relative production rate of 
Shiga toxin produced in 5 strains of 
enterohemorrhagic Escherichia coli 
(4	O80	strains	and	1	O157	strain)	
at subinhibitory concentrations of 
azithromycin,	ciprofloxacin,	and	
ceftriaxone, compared with basal 
production rate (no antibiotics), France, 
January 2005–October 2014. A) Isolate 
35344. B) Isolate 33115. C) Isolate 
35431. D) Isolate 36047. E) Isolate 
EDL933.	Error bars indicate SDs.
Figure 6. Relative production rate of Shiga toxin produced in 
2 strains of enterohemorrhagic Escherichia coli	O80	(isolates	
35344 and 33115) at subinhibitory concentrations of azithromycin, 
ciprofloxacin,	ceftriaxone	(alone	and	in	combination),	compared	





tested the effect of antibiotics in combination (14,39). Our 
combination assay results would suggest that azithromycin 
plus ceftriaxone might be a reasonable choice in cases of 
systemic infection.
These findings should be regarded as preliminary and 
require confirmation. However, despite these promising in 
vitro results and because our assays were performed with-
out measuring cytotoxicity, we cannot yet advocate the use 
of these antibiotics for treatment of patients infected with 
EHEC O80:H2. However, a planned national clinical trial 
in France (NCT02336516) to test the efficacy of azithro-
mycin in children with postdiarrheal HUS might soon pro-
vide some answers.
In conclusion, a clonal group of EHEC O80:H2 
strains of unknown origin and with the ability to induce 
invasive infections and lethality is emerging in France 
and represents a new therapeutic challenge. The interplay 
between intestinal and extraintestinal virulence factors in 
this new hybrid STEC/ExPEC pathotype remains to be 
elucidated. Azithromycin might be a possible option to 
prevent invasive infections caused by EHEC O80:H2, 
whereas azithromycin/ceftriaxone might be useful in 
treating such infections.
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